Rosiglitazone attenuates indoxyl sulphate-induced endothelial dysfunction

Area of Science:

• Cardiovascular Research
• Endothelial Biology
• Pharmacology

Background:

• Indoxyl sulphate is a uremic toxin detrimental to the cardiovascular system.
• Rosiglitazone (RGZ), an insulin sensitizer, offers cardiovascular benefits.
• The effect of RGZ on indoxyl sulphate-induced endothelial damage is unknown.

Purpose of the Study:

• To investigate the protective effects of RGZ against indoxyl sulphate-induced endothelial injury.
• To elucidate the molecular mechanisms underlying RGZ's protective action.

Main Methods:

• In vitro study using endothelial cells.
• Cells were pretreated with RGZ (5 and 10 μmol/L) followed by indoxyl sulphate (100 and 1000 μmol/L) exposure for 48 hours.
• Assessed expression of adhesion molecules (ICAM-1, VCAM-1), inflammatory markers (MCP-1), oxidative stress markers (NOX4, NF-κB), and MAPK pathways (ERK1/2, p38).

Main Results:

• Indoxyl sulphate upregulated ICAM-1, VCAM-1, MCP-1, NOX4, and NF-κB, activating ERK1/2 and p38 MAPK pathways.
• RGZ pretreatment ameliorated endothelial injury.
• RGZ attenuated NOX4 and NF-κB upregulation and prevented ERK1/2 and p38 MAPK activation.

Conclusions:

• RGZ effectively ameliorates indoxyl sulphate-induced endothelial injury.
• RGZ exerts protective effects by inhibiting oxidative stress and inflammatory signaling pathways.
• RGZ shows potential as a therapeutic agent for cardiovascular complications associated with uremia.